Ph.D., Biochemistry, 1989
University of Massachusetts,
B.S., Microbiology, 1983
US Patent and Trademark Office
University of Nebraska
Thompson Coburn LLP
Senior Patent Agent, 2005-Present
Blackwell, Sanders, Peper, Martin LLP
Biotechnology Advisor, 2004
Proteon Therapeutics, Inc.
Scientific Consultant, 2003-2004
Director, Antiviral Screening, 2001-2003
Various Positions Including Director, Hybridization, 1989-2000
Charley draws on his 14 years of biotech industry experience and doctorate in biochemistry to serve clients in the biotech industry and university sectors.
His practice focuses on preparation and prosecution of U.S. and foreign patent applications in biotech and chemical fields, patentability analyses, and evaluation of third party technology.
Prior to joining Thompson Coburn, he served in senior research positions for both large and small biotech companies, where he led teams and collaborations directed to the discovery and commercialization of agbiotech and pharmaceutical products. A named inventor on 22 issued U.S. Patents, Charley made key contributions to the Monsanto YieldGard® Rootworm and Genuity™ VT Double PRO™ lepidopteran insect control products.
Charley takes a business-goal oriented and pragmatic approach to preparing and prosecuting patent applications before the U.S. Patent and Trademark Office as a registered patent agent.
"Expression of Cry3b Insecticidal Protein In Plants," C. Romano. U.S. Patent No. 6,501,009; (12/31/2002)
"Methods for Transforming Plants to Express Cry2Ab. Delta-Endotoxins Targeted to Plastids," D. Corbin and C. Romano. U.S. Patent No. 6,489,542; (12/3/2002)
"Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof," S. Andersen, G. Hicks, J. Huesing, C. Romano, C. Vetsch. U.S. Patent No. 7,612,194; (11/3/2009)
"A Methods and Compositions for Controlling Insects," B. Isaac, J. Greenplate, J. Purcell, C. Romano. U.S. Patent No. 6,372,211; (4/16/2002)
"Nucleic Acid Segments Encoding Modified Bacillus Thuringiensis Coleopteran-Toxic Crystal Proteins," L. English, S. Brussock, T. Malvar, J. Bryson, C. Kulesza, F. Walters, S. Slatin, M. Von Tersch and C. Romano. U.S. Patent No. 6,060,594; (5/9/2000)
"Insect-Resistant Transgenic Plants," L. English, S. Brussock, T. Malvar, J. Bryson, C. Kulesza, F. Walters, S. Slatin, M. Von Tersch and C. Romano. U.S. Patent No. 6,023,013; (2/8/2000)
"Multiple Viral Replicon Culture Systems," J. Dyall, P. Olivo, R. Roth, C. Romano. U.S. Patent No. 6,750,009; (6/15/2004)
Romano CP, Robson PR, Smith H, Estelle M, Klee H. Transgene-mediated auxin overproduction in Arabidopsis: hypocotyl elongation phenotype and interactions with the hy6-1 hypocotyl elongation and axr1 auxin-resistant mutants;
Plant Mol Biol. 1995 Mar;27(6):1071-83
Romano CP, Cooper ML, Klee HJ. Uncoupling Auxin and Ethylene Effects in Transgenic Tobacco and Arabidopsis Plants;
Plant Cell. 1993 Feb;5(2):181-189.
Romano CP, Hein MB, Klee HJ. Inactivation of auxin in tobacco transformed with the indoleacetic acid-lysine synthetase gene of Pseudomonas savastanoi.;
Genes Dev. 1991 Mar;5(3):438-46.
Romano CP, Bienz-Tadmor B, Mariani BD, Kafatos FC. Both early and late Drosophila chorion gene promoters confer correct temporal, tissue and sex specificity on a reporter Adh gene;
EMBO J. 1988 Mar;7(3):783-90.
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.